image: Motria A. Lonchyna, B.S.N., R.N., of Children's National Medical Center in Washington, D.C. received the Lundbeck Neonatal Nursing Career Path Scholarship on Friday, Sept. 25, 2009, at the National Association of Neonatal Nurses Annual Meeting. view more
Credit: National Association of Neonatal Nurses
GLENVIEW, Ill., September 25, 2009 – The National Association of Neonatal Nurses (NANN) is proud to announce the recipients of the Lundbeck Neonatal Nursing Career Path Scholarship. The program, made possible through a grant from Lundbeck Inc. (formerly Ovation Pharmaceuticals), supports clinical neonatal nurses who seek to advance their education and become neonatal nurse practitioners. Recipients Motria A. Lonchyna, BSN, RN of Children's National Medical Center in Washington, D.C., and Taryn M. Edwards, BSN, RNC at Children's Hospital of Philadelphia, will be awarded the scholarship today during NANN's annual meeting in Austin, TX. This is the second year the scholarship has been awarded.
"We are thrilled to award these scholarships to two deserving applicants," said Robin Bissinger, PhD, RNC, NNP, chair of the NANNP Council. "Neonatal nurse practitioners are an essential part of the neonatal healthcare system, and we are excited to have the support of Lundbeck Inc. to assist these highly-qualified nurses in reaching that goal. Each recipient demonstrated a strong commitment to the neonatal community and to improving the care of neonates, infants and their families."
Scholarship recipients were chosen by a special committee of NANN members who conducted a blind review process of all applications to ensure complete impartiality. After a thorough review and consideration of dozens of qualified, motivated and highly skilled nurses, Lonchyna and Edwards were selected as the recipients of the 2009 scholarships.
"Infants in the neonatal intensive care unit (NICU) often require highly specialized care. We at Lundbeck are committed to making a difference in the lives of patients and their families who, like many neonates and their families, are faced with serious and sometimes rare diseases," said Barbara Jackson, Vice President of the NICU and Hematology/Oncology Business Units at Lundbeck Inc. "We congratulate Motria and Taryn on being awarded these scholarships, and thank them for their dedication to the neonatal community."
Scholarship recipient Motria Lonchyna is a level two Registered Nurse (RN II) at Children's National Medical Center in Washington DC. She is also an Extra Corporeal Membrane Oxygenation (ECMO) and Prisma (Continuous Renal Replacement Therapy) specialist, bereavement certified, and a nursing preceptor. In her application, a colleague wrote that Lonchyna was "destined to make a difference."
Taryn Edwards is third level Clinical Nurse at Children's Hospital of Philadelphia. She is chair of the NICU Breastfeeding Committee, and a member of the Maternal-Child Health Leadership Academy. In addition, she serves on numerous other committees within her unit. As part of her application, a colleague wrote, "If I had a critically ill infant, I would want Taryn to be caring for my child."
The scholarship program was created in 2007 following the establishment of a new division within NANN dedicated to neonatal nurse practitioners. The initiative demonstrates Lundbeck's support of NANN's efforts to promote the quality of neonatal care, and to be an advocate for clinical and professional practice and advanced education.
About the National Association of Neonatal Nurses
Founded in 1984, the National Association of Neonatal Nurses (NANN) represents the community of neonatal nurses that provides evidence-based care to high-risk neonatal patients. NANN is recognized as the expert voice that influences standards of practice through advocacy, collaboration, and leadership. A professional nursing society, it supports its members by enabling them to alleviate suffering and protect, promote, and restore health to infants and their families. NANN sponsors an annual conference and publishes Advances in Neonatal Care, a bimonthly, peer-reviewed, medical journal. NANN is headquartered in Glenview, IL. For more information, visit www.NANN.org.
About Lundbeck Inc.
Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by H. Lundbeck A/S and has proven success in developing and commercializing high-need treatments. The company is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available. For more information, please visit www.lundbeckinc.com.
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from CNS disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit www.lundbeck.com.